Arbutus Biopharma Corp Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount
Arbutus Biopharma Corp (ABUS) reported Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsForeign · last filed 2025-03-27
- Arbutus Biopharma Corp effective income tax rate reconciliation, tax credit, foreign, amount for fiscal 2024 was $0.00.
- Arbutus Biopharma Corp effective income tax rate reconciliation, tax credit, foreign, amount for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Arbutus Biopharma Corp effective income tax rate reconciliation, tax credit, foreign, amount for fiscal 2022 was $4.44M.
- Arbutus Biopharma Corp effective income tax rate reconciliation, tax credit, foreign, amount for fiscal 2021 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-27 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-27 |
| 2022-12-31 | $4.44M 10-K · filed 2024-03-05 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |